Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Ellipticine + Valproic acid|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ellipticine||Ellipticine produces DNA damage through intercalation into DNA, inhibition of DNA topoisomerase, and formation of ellipticine-DNA adducts, resulting in cell-cycle arrest and growth inhibition in tumor cells (PMID: 21753906, PMID: 32335141).|
|Valproic acid||Stavzor||Depacon|Valproate Sodium|Depakene||HDAC Inhibitor 44||Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|